Development of an Epstein–Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma in an HIV-1-infected patient following a change in the EBV dominant type

Buisson, Marlyse; Morand, Patrice; Péoc’h, Michel; Bouchard, O; Bourgeat, Marie J.; Seigneurin, J.M.

doi:10.1038/sj.leu.2401268

Cited by 6 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primer pair, designed in the BamH1 C region of EBV DNA, ampli®es a 120 bp product. The sequences of the upper (BC1) and lower (BC2) primers were 5 H -GACAACTCGGCCGTGATGGA-3 H (position 4010± 4029) and 5 H -TGAAGTTGGAGGCGGACGAG-3 H (position 4111±4130), respectively [Buisson et al, 1999]. PCR ampli®cation was performed in a 50 ml volume containing 10 mM Tris HCl, 50 mM KCl, 1.5 mM MgCl 2 , 50 pmoles of each primer, 0.5 U of Taq polymerase (Roche Molecular Biochemicals), 1 U of UDG (Roche Molecular Biochemicals), 200 mM of dATP, dCTP, and dGTP, 570 mM of dUTP, and 30 mM digoxigenin-dUTP.…”

Section: Semiquantitative Elisa-pcrmentioning

confidence: 99%

Routine use of real‐time quantitative PCR for laboratory diagnosis of Epstein‐Barr virus infections

Brengel‐Pesce

Morand

Schmuck

et al. 2002

Journal of Medical Virology

View full text Add to dashboard Cite

Real-time quantitative polymerase chain reaction (PCR) on the LightCycler instrument (LC-PCR) was developed to measure the Epstein-Barr virus (EBV) load in clinical samples. LC-PCR detected two copies of the EBV genome per 500 ng of DNA. Its specificity was confirmed by assays in EBV-negative cell lines, other human herpesviruses and EBV-seronegative individuals. Excellent inter-assay reproducibility of LC-PCR was obtained in 43 samples (r = 0.983). LC-PCR results were compared with a routinely used ELISA-PCR of 150 samples and a good correlation was found (r = 0.956). A total of 88 individuals were studied, including healthy EBV-seropositive adults (n = 32), patients with EBV-associated disease (n = 34), and HIV-infected patients (n = 22); 37.5% of PBMC samples from healthy individuals contained EBV DNA, while no serum sample was positive. The viral load was significantly higher in PBMCS and saliva specimens in patients recently infected with HIV (19 and 39,400 copies/microg DNA, respectively), as well as in AIDS patients (122 and 331,130 copies/microg DNA) than in the control population (0 and 35 copies/microg DNA). This study confirmed that EBV load measurement with LC-PCR is helpful in the management of EBV-related post-transplantation lymphoproliferative disorders and probably of EBV-associated primary central nervous system B-cell lymphoma.

show abstract

Section: Semiquantitative Elisa-pcrmentioning

confidence: 99%

Routine use of real‐time quantitative PCR for laboratory diagnosis of Epstein‐Barr virus infections

Brengel‐Pesce

Morand

Schmuck

et al. 2002

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…The semi-quantitative EBV PCR strategy was adapted from the study of Rooney et al 26 and has already been published. [30][31][32] Briefly, after a phenol chloroform extraction, the PCR assay amplified a 120-bp fragment within the only BamHI C region of EBV. After electrophoresis, the DNA fragments were transferred to nylon membranes and hybridized to a 32 P-ATP-labelled BamHI C-specific DNA probe.…”

Section: Semi-quantitative Pcrmentioning

confidence: 99%

A prospective study of Epstein–Barr virus load in 85 hematopoietic stem cell transplants

Bueltzingsloewen

Morand

Buisson

et al. 2002

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Summary:EBV viral load (EBV-VL) in PBMC was prospectively determined by semi-quantitative PCR in 85 stem cell transplants (40 genoidentical, 45 non-genoidentical) in order to characterize the kinetics of EBV-VL and to assess the ability of this measure to predict the development of EBV-induced lymphoproliferative disease (EBV-LPD). PCR was performed prior to and after transplantation. An EBV-VL Ͼ300 copies/ g DNA was chosen as the threshold for risk of developing an EBV-LPD. Two hundred and fifty-eight EBV-VL measures were evaluable. Five patients (5.9%) developed an EBV-LPD. All had an elevated EBV DNA peak level before EBV-LPD. Fifteen out of 80 recipients (18.7%) without EBV-LPD had EBV levels over 300 copies/ g DNA at least once during the follow-up. Overall, the manifestation of at least one EBV-VL over 300 copies/ g DNA during the entire follow-up demonstrated a sensitivity, specificity, positive and negative predictive value for the diagnosis of EBV-LPD of 100%, 81%, 25% and 100%, respectively. In patients without EBV-LPD, HLA incompatibility, grade уII acute GVHD and use of an unmanipulated graft were significantly associated with an EBV-VL Ͼ300 copies/ g DNA. This strategy appears sensitive for the diagnosis of EBV-LPD but its positive predictive value has to be improved in order to guide pre-emptive therapy.

show abstract

“…We observed a prevalence of EBV-1 among HIV/EBV coinfected patients, confirming the epidemiology of the herpesvirus analyzed in different organ tissues of PLHIV with different clinical profiles 51 , 52 . Reports of EBV-2 prevalence in coinfected patients occur in specific clinical conditions after transient reactivation events of cell sites infected by different types of EBV 53 .…”

Section: Discussionmentioning

confidence: 99%

Epidemiological risk factors associated with primary infection by Epstein–Barr virus in HIV-1-positive subjects in the Brazilian Amazon region

Pereira

França

Costa

et al. 2021

Sci Rep

View full text Add to dashboard Cite

To identify the prevalence and risk factors for primary Epstein–Barr virus (EBV) infection in human immunodeficiency virus (HIV)-1-positive adult treatment-naïve patients between January 2018 and December 2019 in a state of the Brazilian Amazon region. A total of 268 HIV-1 positive patients and 65 blood donors participated in the study. Epidemiological data were obtained from medical records and through a designed questionnaire. EBV infection was screened by the semiquantitative detection of anti-viral capsid antigen (VCA) EBV IgM and IgG, followed by molecular detection of the EBNA-3C gene. The plasma viral loads of HIV-1 and EBV were quantified using a commercial kit. The prevalence of primary coinfection was 7.12%. The associated risk factors were education level, family income, history of illicit drug use and sexually transmitted infections, homosexual contact and condom nonuse. Approximately 58.5% had late initiation of highly active antiretroviral therapy, which influenced the risk of HIV-EBV 1/2 multiple infection (odds ratio (OR): 4.76; 95% CI 1.51–15.04) and symptom development (p = 0.004). HIV viral load was associated with patient age (OR: 2.04; 95% CI 2.01–2.07; p = 0.026) and duration of illicit drug use (OR: 1.57; 95% CI 1.12–2.22; p = 0.0548). EBV viral load was associated with younger age (OR: 0.82; 95% CI 0.79–1.03; p = 0.0579). The replication of both viruses was associated with symptom development (HIV = OR: 2.06; 95% CI 1.22–3.50; p = 0.0073; EBV = OR: 8.81; 95% CI 1–10; p = 0.0447). The prevalence of HIV/EBV coinfection was lower than that observed in other studies, and social vulnerability and promiscuous sexual behavior were associated risk factors. A long time of HIV-1 infection, without therapy, influenced the risk of coinfection and disease progression. The viral loads of both viruses may be associated with some epidemiological aspects of the population.

show abstract

Development of an Epstein–Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma in an HIV-1-infected patient following a change in the EBV dominant type

Cited by 6 publications

References 6 publications

Routine use of real‐time quantitative PCR for laboratory diagnosis of Epstein‐Barr virus infections

Routine use of real‐time quantitative PCR for laboratory diagnosis of Epstein‐Barr virus infections

A prospective study of Epstein–Barr virus load in 85 hematopoietic stem cell transplants

Epidemiological risk factors associated with primary infection by Epstein–Barr virus in HIV-1-positive subjects in the Brazilian Amazon region

Contact Info

Product

Resources

About